MX2023011163A - Formulaciones para vacuna contra coronavirus. - Google Patents
Formulaciones para vacuna contra coronavirus.Info
- Publication number
- MX2023011163A MX2023011163A MX2023011163A MX2023011163A MX2023011163A MX 2023011163 A MX2023011163 A MX 2023011163A MX 2023011163 A MX2023011163 A MX 2023011163A MX 2023011163 A MX2023011163 A MX 2023011163A MX 2023011163 A MX2023011163 A MX 2023011163A
- Authority
- MX
- Mexico
- Prior art keywords
- nanoparticles
- vaccine formulations
- coronavirus vaccine
- vaccines
- disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164487P | 2021-03-22 | 2021-03-22 | |
| US202163176825P | 2021-04-19 | 2021-04-19 | |
| US202163177059P | 2021-04-20 | 2021-04-20 | |
| US202163195986P | 2021-06-02 | 2021-06-02 | |
| US202163280395P | 2021-11-17 | 2021-11-17 | |
| US202163290439P | 2021-12-16 | 2021-12-16 | |
| US202163292196P | 2021-12-21 | 2021-12-21 | |
| US202163293468P | 2021-12-23 | 2021-12-23 | |
| PCT/US2022/020974 WO2022203963A1 (en) | 2021-03-22 | 2022-03-18 | Coronavirus vaccine formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011163A true MX2023011163A (es) | 2024-02-27 |
Family
ID=83396030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011163A MX2023011163A (es) | 2021-03-22 | 2022-03-18 | Formulaciones para vacuna contra coronavirus. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220332765A1 (https=) |
| EP (1) | EP4313143A4 (https=) |
| JP (1) | JP2024511412A (https=) |
| KR (1) | KR20230160349A (https=) |
| AU (1) | AU2022245141A1 (https=) |
| BR (1) | BR112023019301A2 (https=) |
| CA (1) | CA3213221A1 (https=) |
| IL (1) | IL306088A (https=) |
| MX (1) | MX2023011163A (https=) |
| TW (1) | TW202304955A (https=) |
| WO (1) | WO2022203963A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120227451A (zh) * | 2018-03-19 | 2025-07-01 | 诺瓦瓦克斯股份有限公司 | 多价流感纳米颗粒疫苗 |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| WO2024151583A2 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| WO2024258829A1 (en) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025054236A2 (en) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025088585A1 (en) * | 2023-10-25 | 2025-05-01 | Novavax AB | Saponin-based adjuvants and methods of characterizing same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968510B1 (en) * | 2013-03-14 | 2019-10-09 | President and Fellows of Harvard College | Nanoparticle-based compositions |
| US10953089B1 (en) * | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| US20210228707A1 (en) * | 2020-01-28 | 2021-07-29 | Modernatx, Inc. | Coronavirus rna vaccines |
| JP2023512519A (ja) * | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| US10906944B2 (en) * | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
-
2022
- 2022-03-18 CA CA3213221A patent/CA3213221A1/en active Pending
- 2022-03-18 EP EP22776366.1A patent/EP4313143A4/en active Pending
- 2022-03-18 JP JP2023558130A patent/JP2024511412A/ja active Pending
- 2022-03-18 MX MX2023011163A patent/MX2023011163A/es unknown
- 2022-03-18 AU AU2022245141A patent/AU2022245141A1/en active Pending
- 2022-03-18 IL IL306088A patent/IL306088A/en unknown
- 2022-03-18 WO PCT/US2022/020974 patent/WO2022203963A1/en not_active Ceased
- 2022-03-18 BR BR112023019301A patent/BR112023019301A2/pt unknown
- 2022-03-18 KR KR1020237036140A patent/KR20230160349A/ko active Pending
- 2022-03-22 TW TW111110461A patent/TW202304955A/zh unknown
- 2022-03-22 US US17/700,945 patent/US20220332765A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022245141A9 (en) | 2024-02-22 |
| JP2024511412A (ja) | 2024-03-13 |
| EP4313143A4 (en) | 2025-06-18 |
| BR112023019301A2 (pt) | 2023-12-05 |
| AU2022245141A1 (en) | 2023-10-05 |
| CA3213221A1 (en) | 2022-09-29 |
| KR20230160349A (ko) | 2023-11-23 |
| US20220332765A1 (en) | 2022-10-20 |
| IL306088A (en) | 2023-11-01 |
| EP4313143A1 (en) | 2024-02-07 |
| TW202304955A (zh) | 2023-02-01 |
| WO2022203963A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023011163A (es) | Formulaciones para vacuna contra coronavirus. | |
| ZA202401922B (en) | Coronavirus vaccine formulations | |
| MX2024006589A (es) | Formulaciones de vacunas contra el coronavirus. | |
| MX2018002728A (es) | Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas. | |
| CY1121211T1 (el) | Εμβολιο ιου ερπητα ζωστηρα | |
| CO2019002955A2 (es) | Composiciones de vacuna neumocócica multivalente que comprenden conjugados de polisacáridos y proteínas | |
| ECSP22072586A (es) | VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG | |
| MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
| UY37811A (es) | Una composición inmunogénica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparación de la misma | |
| MXPA05008340A (es) | Microbios de vida libre modificados, composiciones de vacuna y metodos de uso de los mismos. | |
| CR10559A (es) | Vacuna de influenza | |
| AR092896A1 (es) | Composiciones inmunogenicas | |
| NO20023829L (no) | Proteosom influensavaksine | |
| AR032597A1 (es) | Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli | |
| AR011216A1 (es) | Una vacuna a base de antigenos superficiales contra la gripe, un metodo para prepararla y un metodo para la preparacion de proteinas antigenicas superficiales a partir de virus de gripe propagados sobre un cultivo celular animal | |
| CL2015001900A1 (es) | Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina. | |
| MX2018010291A (es) | Vacunas novedosas contra el virus de zika. | |
| CO2022012272A2 (es) | Vacunas contra el coronavirus y métodos de uso | |
| CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
| BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
| MX2021004478A (es) | Dispositivo hiperbarico y metodos para producir vacunas inactivadas y para replegar/solubilizar proteinas recombinantes. | |
| MX2017011322A (es) | Sistema de marcadores, en particular para antigenos subunitarios expresados por baculovirus. | |
| CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
| ECSP22064620A (es) | COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2 | |
| AR089995A1 (es) | Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas |